Prot# AT-101-CS-005: Phz 2, Opn Lbl, Mltctr Study of Single-Agent AT-101 in Pts w/ Relapsed or Refractory B-Cell Malignancies (Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma, or Small Lymphocytic Lympoma/Chronic

Project: Research project

Project Details

StatusFinished
Effective start/end date3/24/062/1/12

Funding

  • Ascenta Therapeutics, Inc. (AT-101-CS-005)